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ABSTRACT 
Highly pathogenic avian influenza (HPAI) H5N1 viruses continue to be endemic in many 
Asian countries causing lethal infections in human. The vaccine virus (NIBRG-14) developed 
from a H5N1 virus strain (A/Vietnam/1194/2004) has been approved by WHO for use in human 
as well as poultry vaccine. It is well-known that the A/H5N1 viruses have diversified both 
genetically and antigenically allowing them to escape from the host immune surveillance 
system. Therefore, evaluation of the vaccine immunogenicity and its relationship to newly 
emerging viruses is crucially important. NIBRG-14 virus particles propagated in embryonated 
chicken eggs were inactivated with formalin and adjuvanted with mineral oil to form a water-in-
oil emulsion. The resulting vaccine was injected subcutaneously into chickens and ducks. The 
vaccinated birds were challenged with the HPAI virus strains circulating in Vietnam including 
clade 1, clade 2.3.2.1a and 2.3.2.1b at day 21 post-vaccination (p. v.). We observed that 
vaccinated birds were protected from manifestation of disease signs upon challenge with HPAI 
clade 1 and clade 2.3.2.1a viruses; however, it did not confer protection against clade 2.3.2.1b 
challenge andstressing the need for development of new effective vaccines against the newly 
emerging viruses. 
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1. INTRODUCTION 
Since the first human case of H5N1 was reported in Hongkong - Special Administrative 
Region (SAR), H5N1 has spread among birds out of East Asia and in far west of England and 
West Africa, tend to spread into American and Australian continents. There are total of 565 
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human cases have been confirmed by WHO by August 2011, with a very high case fatality rate 
of 60 % [1, 2] and millions of poultry were killed and culled of influenza. The outbreakof avian 
influenza A (H5N1) in Vietnam over years has caused major morbidity and mortality, and severe 
economic consequences [3]. Therefore, prepandemic H5N1 vaccines have been thus developed 
and tested. Shortage of vaccine is of particular concern in developing countries. It is estimated 
that global production capacity of seasonal influenza vaccines is of approximately 350 million 
doses and mostly in production plants located in industrialized countries [4]. As part of the 
preparedness plan for an influenza pandemic in Vietnam, H5N1 vaccine was produced in our 
laboratory using e’;/mbryonated chicken egg-based technology [5]. This vaccine strain (NIBRG-
14) was produced from a human isolate (A/Vietnam/1194/2004 [H5N1]) of a virulent clade 1 
influenza A (H5N1) virus by reverse genetic technology and now is being used in many 
countries including Vietnam to prevent H5N1 infections.  
A recent review of H5N1 influenza A virus sublineages in Vietnam has shown the presence 
of emerging H5N1 virus clades. In the northern of Vietnam, two clades of 2.3.2.1a and 2.3.4 are 
known to be the most common ones. Meanwhile clade 1 still circulates and causes outbreaks in 
southern provinces of Vietnam [3, 6]. NCVD’s systematic surveillance recently update the 
presenting of clade 7 [7], and clade 2.3.2.1b. According to CDC and WHO surveillance, H5N1 
virus clade 2.3.2.1b is not new. It was first detected in poultry during 2009 in Vietnam and 
evolved from viruses that had previously been circulating in Vietnam since 2005. Till now, the 
clade 2.3.2.1b viruses are very highly pathogen with high resistance to almost vaccine strains 
and are spreading more widely in poultry and wild birds. 
The FAO report indicated the fact that the H5N1 poultry vaccines currently being used in 
Vietnam do not protect poultry against the new H5N1 clades[8]. Here we aimed to assess 
whether the vaccine strain NIBRG-14 can induce protective immunity and protect poultry from 
clade 1, 2.3.2.1a and 2.3.2.1b strain infections. 
2. MATERIALS AND METHODS 
2.1. Virus andvaccine 
A/H5N1 viruses (clade 1, clade 2.3.2.1a and 2.3.2.1b) were isolated from dead chickens 
during the outbreak of HPAI in Vietnam and provided by National Center for Veterinary 
Diagnosis. The vaccine used in this study was produced from the reverse genetics H5N1 master 
seed (called NIBRG-14) generated with the modified genes H5 and N1 from the strain 
A/Vietnam/1194/2004(H5N1) and the rest of the backbone segments (PB2, PB1, PA, NP, M, 
NS) from the A/Puerto Rico/8/34(H1N1) strain by the National Institute for Biological 
Standards and Control (NIBSC), UK [9]. Vaccine virus was propagated in the allantoic cavity of 
10-day-old embryonic hen’s egg. Allantoic fluid was harvested 72 hours post infection and was 
clarified at high speed (8000 rpm, 10 min, 4ºC, in a Sorval rotor) [10]. The virus was harvested 
and inactivated with formalin and adjuvanted with mineral oil to form a water-in-oil emulsion 
vaccine. 
2.2. Chicken, Duck, and vaccine administration 
Two week old specific antibody negative (SAN) chickens ISA Brown hybrid(body weight 
100 ± 0.8 g) and ducks Super M (body weight 250.0 ± 1 g) were purchased from the Company 
of Poultry (Hanoi, Vietnam). The birds were divided into 3 groups of 10 birds each (10 
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experimental, 3 as control) for each of the chicken and duck groups, respectively (table 1). The 
experimental groups were vaccinated as follows: 1st dose (160 HAU in 0.5 ml/dose via the 
subcutaneous route) was given at 14 days old and the 2nd dose (booster dose) was given again in 
exactly the same way 21 days after the first injection. Blood was collected from the single 
vaccinated, booster vaccinated, and control groups at days 21 (before challenge). Evaluation was 
based on antibody titer by HI. A HI titer > 3.0 log2 is considered protective [11 - 14] 
2.3. Challenge and clinical monitoring 
The vaccinated birds were challenged with highly pathogenic A/H5N1 viruses (clade1, 
clade 2.3.2.1a and clade 2.3.2.1b) according to the World Health Organization manual [2]. 
Briefly, each of birds was inoculated with 0.1 ml of the infectious virus by the intranasal route at 
day 21 after vaccination; upon the single dose and booster dose, respectively. Clinical signs, 
mortality, and weight were monitored after the challenge. Serum samples were collected from all 
birds before challenge to test for the presence of antibodies against H5N1 clade 1, clade 2.3.2 
and clade 2.3.2.1 by HI test. 
2.4. HemagglutinationInhibition Test 
Antibodies in the serum samples were determined by HI test according to WHO 
manual[15]. Briefly, a duplicate serial 2-fold dilution of each test serum (pretreated at 56oC for 
30 min to inactivate nonspecific inhibitors) was made. Sera in wells were then incubated with 4 
HA units of the H5 antigen purchased from the National Institute of Veterinary Research, Hanoi, 
Vietnam (clade 1.0 of the A/H5N1 subtype; a dominant clade in Vietnam and the Southeast 
Asian countries), for 15 min at room temperature. Control wells were filled with phosphate-
buffered saline (1× PBS). Then 0.5 % (v/v) suspension of bird red blood cells (RBC) was added 
to each well. The HI antibody titer was determined as described by [16]. Antibody titer 
corresponding to the reciprocal of the highest serum dilution that still inhibited hemagglutination 
was recorded as the realistic HI titer expressed as a log2 value. The geometric mean titer (GMT) 
of HI antibodies of each group was determined and compared, and titer equal to or greater than 3 
log2 were considered positive [11, 17, 18]. 
2.5. Real-time RT-PCR assay 
All vaccinated chickens and ducks were throat swabs collected at day 3 and after virus 
challenge. Total cellular RNA was isolated from the birds using TRIzol reagent 
(Invitrogen)according to the manufacturer’s instructions with some modification [19]. Reverse 
transcription was carried out with the Superscript TM III First-Strand Synthesis System for RT-
PCR (Invitrogen). The cDNA was then used as a template for PCR using H5 specific primers. 
2.6. Statistical Analysis 
The 10 birds are considered technical replicates. For the studies on the immunogenicity of 
vaccines, the titer in each chick was considered an independent experimental unit for analysis. 
Data are presented as Mean ± S. D. Comparisons between experimental groups were analyzed 
by Student’s t test. A value of 0.05 was used to determine statistical significance in all analyses. 
P values < 0.05 were considered to be statistically significant. 
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3. RESULTS 
3.1. Immune response of vaccinated birds to NIBRG-14 
Two groups of SAN animals including 60 chickens and 60 ducks were used for the animal 
experiments of antibody response in animals. The vaccine (NIBRG-14) was injected into 2-
week-old chickens and ducks as described above. We observed that 3-5 percent of vacinated 
birds exhibited signs of weakness in the first 3 days after vaccination but grown normally after 
the next 3 days. There was no inflammatory syndrome at injecting side; no fever or death was 
observed for the vaccinated birds.  
Serum samples of the vaccinated birds collected every 3 weeks were examined for 
antibodies to the vaccine strain, NIBRG-14, by HI test using H5N1 antigen 
(A/chiken/Scotland/59). 






HAI Unit – 
GMTlog2 No. of 
ducks(Positive/ 
Total) 










1 7/10 3.7 0 6/10 3.2 0 
2.3.2.1a 8/10 4.4 0 4/10 3.1 0 
2.3.2.1b 8/10 3.9 0 5/10 3.4 0 
Total (%) 23/30 (76.6 %) 4.0 0 15/30 (50 %) 3.2 0 
2nddose 
1 10/10 6.7 0 9/10 5.0 0 
2.3.2.1a 10/10 6.2 0 10/10 4.8 0 
2.3.2.1b 10/10 6.5 0 8/10 4.4 0 
Total (%) 30/30 (100 %) 6.46 0 27/30 (90 %) 4.7 0 
The result showed that two weeks after the 1st dose, 76 % of vaccinated chickens induced 
immune response to hemagglutinin antigen; average unit (GMT) was at 4 log2. However, 3 
weeks after the 2nd boosting dose 100 % of examined chickens are positive to HA antibody; 
GMT was at 6.46 log2. Whilst they are 50 %, 3.2 log2 and 90 % and 4.7 log2 in vaccinated 
ducks after they received the one dose and two doses, respectively (table 1). Whereas, in the 
control birds who received PBS instead of vaccine, the immune response was not observed 
(table 1). This data indicated that the vaccine used in the study was protective. We also observed 
the body weight of immunized animals compared to the control group. No differences were 
recorded between the vaccinated animals and control subjects (data not shown). By HI, the 
vaccine induced seroconversion at rates exceeding the required criteria [11-14, 20] against the 
NIBRG-14 strain. Thus, vaccine quality could be considered good to use. 
3.2. Challenge with H5N1 virus clade 1, clade 2.3.2.1a and clade2.3.2.1b 
To evaluate the efficacy of NIBRG-14 vaccine against the most common H5N1 clades 
circulating in Vietnam, we performed two experiments (tables 2). The first determined the 
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efficacy of a single dose of vaccine followed by a challenge dose of the clade 1, clade 2.3.2.1a 
and clade 2.3.2.1b. In the second experiment, the birds received two doses of vaccine and 
challenged with the above HPAI viruses (table 2). 
Two-week-old SPF chickens and ducks were vaccinated with a clade 1 whole-virus vaccine 
(NIBRG-14) and then challenged intranasally with the clade 1, clade 2.3.2.1a and clade 2.3.2.1b 
with 106TCID50/unit. Ten chickens or ducks were used for challenging with each virus clades. 
Disease signs were observed post challenging (p.c). The survival rates of the chickens 
challenged with each of the three HPAI viruses were shown in table 2. In the chicken group 
which received only single dose of vaccine, 20 % of vaccinated chickens died within 5 days after 
challenge with clade 1 (H5N1); and they were 20 % and 100 % for those injected with clade 
2.3.2.1a and clade 2.3.2.1b, respectively. In contrast, all of the control chickens died within 5 
days p.c. Similarly, in the chicken group which received two doses of vaccine, we observed that 
the survival rates were 80 %, 100 % and 10 % as they were vaccinated with clade 1, clade 
2.3.2.1a and clade 2.3.2.1b, respectively. The bird that died had the lowest HI titer to the 
challenge virus (data not shown). 
Likewise, the ducks which received one dose of vaccine had survival rate of 90 %, 100 % 
and 10 % when challenged with clade 1, clade 2.3.2.1a and clade 2.3.2.1b, respectively (Table 
2). All ducks who received 2 doses of vaccine induced immune response to HPAI viruses but 
with varied survival rates as 100 %, 100 % and 30 % to clade 1, clade 2.3.2.1a and clade 
2.3.2.1b, respectively. Meanwhile in the control group these were 20 %, 60 % and 0 % when 
ducks were infected with clade 1, clade 2.3.2.1a and clade 2.3.2.1b, respectively. The results 
indicated that ducks were somehow more relatively resistant to HPAI viruses as compared to 
chickens. In other words, chickens were more susceptible to the H5N1 HPAI virus. 
Table 2. Imunized chickens and ducks challenge with H5N1 virus clade 1, clade 2.3.2.1a and clade 2.3.2.1b 
Vaccination Challenge 
virus 
Vaccinated group Control group 
No. of 
birds Alive/total Total Dead/total 
Chicken received 
single dose 
1 10 8/10 (80 %) 5 5/5 (100 %) 
2.3.2.1a 10 8/10 (80 %) 5 5/5 (100 %) 
2.3.2.1b 10 0/10 (0 %) 5 5/5 (100 %) 
Chicken received 
boosted 
1 10 8/10 (80 %) 5 5/5 (100 %) 
2.3.2.1a 10 10/10 (100 %) 5 5/5 (100 %) 
2.3.2.1b 10 1/10 (10 %) 5 5/5 (100 %) 
Duck received 
single dose 
1 10 9/10 (90 %) 5 4/5 (80 %) 
2.3.2.1a 10 10/10 (100 %) 5 2/5 (40 %) 
2.3.2.1b 10 1/10 (10 %) 5 5/5 (100 %) 
Duck received 
boosted 
1 10 10/10 (100 %) 5 4/5 (80 %) 
2.3.2.1a 10 10/10 (100 %) 5 2/5 (40 %) 
2.3.2.1b 10 3/10 (30 %) 5 5/5 (100 %) 
  
Dau Huy Tung, Dong Van Quyen, Nguyen Tung, Tran Xuan Hanh, Kim Young Bong 
 78
3.3. Detection of virus sheding by Real-time RT-PCR 
It is known that once vaccinated, animals will be able to inhibit viral multiplication and 
then neutralize them. The sensitivity of chickens and ducks to H5N1 viruses are known to be 
different. A number of studies have revealed that ducks are more resistant to the viruses which 
are highly pathogenic for chickens[21-23].To assess the viral replication in the immunized 
animals and in the control group we used Real-time RT-PCR assay. The results are presented in 
Table 3. We observed that almost vaccinated animals were capable of inhibiting viral 
replication. The virus multification were significantly decreased (2-3 fold reductions) in all 
vaccinated birds compared to that of the control subjects. These results are well consistent with 
that of HI assay (table 1) which also showed the low virus titer in vaccinated birds and with the 
survival rates determined by challenging (table 2). The virus replicated very strongly in control 
subjects, especially in unvaccinated chickens (table 2). 
Table 3. Virus multiplication in chickens and ducks 3 days post challenging determined by real-time PCR assay 
Vaccination Challenge 
virus 






duck Control duck 
Bird received 
single dose of 
vaccine 
1 1.3 3.4 1.1 1.8 
2.3.2.1a 2.0 3.6 1.4 2.8 




1 1.8 3.2 1.0 1.8 
2.3.2.1a 1.5 3.0 0.5 3.0 
2.3.2.1b 2.0 3.0 2.4 3.0 
Value range from 0 to 5; 4 ultra high (Ct < 20); 3 is high (Ct = 20-25); 2 is normnal (Ct = 
25-30); 1 is low (Ct = 30-35); and 0 is none (Ct >35). 
4. DISCUSSION 
Avian Influenza type A is highly pathogenic and is able to infect a wide host range, 
potentially resulting in epidemics and pandemics. The divergence of influenza H5N1 viruses 
into several clades challenges the efforts of finding antigenically appropriate vaccines to control. 
In reassortment, the unique, segmented nature of influenza viruses allows for the mixing and 
matching of genes that may lead to the creation of a novel subtype. Additionally, the emergence 
of a new clade with different antigenic properties and antiviral susceptibilities than previous outbreak 
strains in Vietnam, re-enforce the need for timely surveillance and development of new vaccine 
strains. It has been reported that prior to 2007, HPAI H5N1 viruses isolated from poultry and humans 
in Vietnam were mainly clade 1 viruses [24]. However in recent lines of evidences indicated that 
emerging clades (clade 2.3.2.1a, clade 2.3.2.1b) are frequently circulating in Vietnam. 
To prevent H5N1 spreading and/or infections, effective vaccines are required. The NIBRG-
14 vaccine strain belongs to clade 1. It is clear that the efficacy of the vaccine is contingent upon 
the degree of match that exists between the vaccine and challenge strains. In this study, we 
conducted the test to assess whether the vaccine strain (NIBRG-14), a reverse-genetics-derived 
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2:6 reassortant between A/Vietnam1994/2004 (H5N1) and A/Puerto Rico (PR)/8/34, provided 
by WHO can induce cross-reactive immunity to the most common HPAI viruses in Vietnam. 
Our data suggested that NIBRG-14 vaccine provides sufficient immunogenicity and 
induces comparable amounts of anti-HA antibodies in vaccinated animals. The vaccine induced 
protective immunity and protected 80 % to 100 % chickens and ducks from clade 1 and clade 
2.3.2.1a viruses challenge. In fact, we found that this vaccine is less or even no effective to clade 
2.3.2.1b. At present we cannot speculate the exact mechanism of how viruses clade 2.3.2.1b 
escaped from its host immune surveillance system induced by NIBRG-14 vaccine. In other 
words, further studies need to be carried out to characterize H5N1 HPAIV clade 2.3.2.1b in 
order to understand why and how this strain is resistant to the NIBRG-14 vaccine strain.  
Taken together, this study provides new insights into the protective immunity elicited by 
currently stockpiled H5N1 (NIBRG-14) vaccine and suggests that new clade 2.3.2.1b should be 
selected as a based source for vaccine seed viruses in Vietnam. 
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TÓM TẮT 
ĐÁNH GIÁ HIỆU LỰC VACCINE CÚM A H5N1 CHỦNG NIBRG-14 DỐI VỚI MỘT SỐ 
CLADE VIRUS CÚM A H5N1 PHÂN LẬP Ở VIỆT NAM NĂM 2011 
Virus độc lực cao cúm A H5N1 liên tục gây ra các vụ đại dịch tạirất nhiều quốc gia châu Á 
trên gia cầm và lây lan sang người. Vaccine cúm A chủng NIBRG-14 phát triển dựa trên chủng 
virus độc lực cao A/Vietnam/1194/2004 được WHO khuyến nghị sử dụng trên gia cầm và 
người. Như chúng ta đã biết virus cúm A H5N1 có khả năng biến đổi đặc tính di truyền và kháng 
nguyên lien tục và đa dạng để thoát khỏi hệ thống miễn dịch của vật chủ. Chính vì vậy, việc 
đánh giá hiệu lực vaccine và khả năng đáp ứng với các chủng virus mới là thật sự cần thiết. 
Virus chủng NIBRG-14 được nhân lên trong phôi gà, bất hoạt bằng formalin và nhũ dầu để tạo  
vaccine, sau đó gây miễn dịch cho gà và vịt thí nghiệm qua đường tiêm dưới da cổ. Các động vật 
thí nghiệm được thử thách công cường độc bằng các virus độc lực cao thuộc clade 1, clade 
2.3.2.1a và clade 2.3.2.1b vào ngày thứ 21 sau khi gây miễn dịch. Chúng tôi nhận thấy các động 
vật được tiêm chủng đều tạo đáp ứng miễn dịch tốt và có khả năng bảo hộ đối với các chủng 
virus thuộc clade 1 và 2.3.2.1a. Tuy nhiên vaccine này lại không hoặc bảo hộ kém đối với clade 
2.3.2.1b. Kết quả của nghiên cứu này gợi ý rằng cần phải phát triển vaccine mới cho chủng virus 
cúm đang lưu hành tại Việt Nam 
Từ khóa. Vắc xin, cúm gia cầm. 
